MFN Drug Pricing Targets: Lowering U.S. Drug Co...

By Rene Pretorius

May 21, 2025

Summary The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) have set Most-Favored-Nation (MFN)
Drug Pricing Analysis: ICER’s Launch Price and Access Report Aims to En...
Trends in Anticancer Drug Pricing: Analyzing Medicare Launch Prices and Impac...
Publication Delays Impact Careers of Early-Career Researchers
A System Dynamics Approach to Lowering Drug Prices by 30–80% in the US
Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030
Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control
FDA AI Drug Approval
HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel
Wegovy CVS Deal: Hybrid Market Access Strategy Insights
Assessing Risks and Opportunities: The Impact of the CDC Hepatitis Lab Closure
Promising Results for Peanut Oral Immunotherapy
Defunding Scientific Research: Implications and Misconceptions in GawandeR...